China Pharma Holdings (CPHI) EBT Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
China Pharma Holdings (CPHI) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 625.00 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -2,179.00 |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -977.00 |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1,581.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -861.00 |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | -9,974.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9,974.00 |
| Mar 31, 2026 | -9,195.00 |
| Dec 31, 2025 | -5,641.00 |
| Sep 30, 2025 | -4,593.00 |
| Jun 30, 2025 | 356.00 |
| Mar 31, 2025 | -495.00 |
| Dec 31, 2024 | -7,403.00 |
| Sep 30, 2024 | -5,983.00 |
| Jun 30, 2024 | -12,134.00 |
| Mar 31, 2024 | -3,725.00 |
| Dec 31, 2023 | -1,607.00 |
| Sep 30, 2023 | -105.00 |
| Jun 30, 2023 | -5,436.00 |
| Mar 31, 2023 | 1,319.00 |
| Dec 31, 2022 | 57,164.00 |
| Sep 30, 2022 | -1,073.00 |
| Jun 30, 2022 | -2,245.00 |
| Mar 31, 2022 | -4,992.00 |
| Dec 31, 2021 | 20,012.00 |
| Sep 30, 2021 | 4,597.00 |